MII Microislet

MicroIslet Reports Positive Preclinical Data to the International Congress of the Transplantation Society SAN DIEGO, Sept. 8 /PRNewswire-FirstCall/ -- MicroIslet Inc. (AMEX:MII) today announced that positive data from its preclinical study at The Scripps Research Institute will be presented at The XX International Congress of the Transplantation Society being held in Vienna, Austria on September 5-10, 2004. The presentation entitled "Use of Alginate Encapsulation as a Strategy for Successful Pig Islet Xenotransplantation" is based on new innovations from MicroIslet's laboratories and data from MicroIslet's ongoing study being conducted in collaboration with The Scripps Research Institute in La Jolla, California under the supervision of Dr. Daniel Salomon, Associate Professor, Department of Molecular and Experimental Medicine. The results show that microencapsulated porcine islets have been able to maintain normal blood glucose levels for up to 250 days in mice with a normal immune system, without the need for immunosuppression. About MicroIslet MicroIslet is a biotechnology company engaged in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with insulin-dependent diabetes. MicroIslet's patented islet transplantation technology, exclusively licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection (microencapsulation) of islet cells. MicroIslet is working to develop and commercialize a first product, called MicroIslet-P(TM), a microencapsulated porcine islet cell suspension that will be used for transplantation in patients with insulin-dependent diabetes. About The Scripps Research Institute The Scripps Research Institute is one of the world's largest, private, non-profit biomedical research organizations. It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune diseases, cardiovascular diseases and synthetic vaccine development. It is dedicated to the creation of basic knowledge in the biosciences for medical application and the betterment of human health, to the pursuit of fundamental scientific advances through interdisciplinary programs and collaborations, and to the education and training of researchers from around the world preparing to meet the scientific challenges of the future. Except for the historical information contained herein, the matters set forth in this press release, including the expectation of development of new therapeutic products, and the impact of MicroIslet's products on diabetes patients, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties inherent in medical treatment discovery, development and commercialization, the risks and uncertainties associated with MicroIslet's early stage xenotransplantation technologies, the risks and uncertainties of governmental approvals and regulation, MicroIslet's need to raise substantial additional capital to proceed through human clinical trials and bring any product to market, the risks that MicroIslet's competitors will develop or market technologies or products that are more effective or commercially attractive than MicroIslet's products, and other risks detailed from time to time in MicroIslet's most recent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. MicroIslet disclaims any intent or obligation to update these forward-looking statements. For more information, please visit our Web site at http://www.microislet.com/. For further information, please contact: Haro Hartounian, Ph.D., President and Chief Operating Officer of MicroIslet, Inc., +1-858-657-0287, . DATASOURCE: MicroIslet, Inc. CONTACT: Haro Hartounian, Ph.D., President and Chief Operating Officer of MicroIslet, Inc., +1-858-657-0287, Web site: http://www.microislet.com/

Copyright